Identification of novel pheno-groups in heart failure with preserved ejection fraction using machine learning
暂无分享,去创建一个
Sanjiv J. Shah | J. Daubert | L. Lund | Å. Hedman | L. Buckbinder | E. Donal | D. Ziemek | L. Gan | C. Linde | M. Brosnan | A. Mälarstig | C. Hage | A. Sharma
[1] Erwan Donal,et al. How to diagnose heart failure with preserved ejection fraction: the HFA-PEFF diagnostic algorithm: a consensus recommendation from the Heart Failure Association (HFA) of the European Society of Cardiology (ESC). , 2019, European heart journal.
[2] G. Filippatos,et al. Comprehensive in‐hospital monitoring in acute heart failure: applications for clinical practice and future directions for research. A statement from the Acute Heart Failure Committee of the Heart Failure Association (HFA) of the European Society of Cardiology (ESC) , 2018, European journal of heart failure.
[3] L. Groop,et al. Novel subgroups of adult-onset diabetes and their association with outcomes: a data-driven cluster analysis of six variables. , 2018, The lancet. Diabetes & endocrinology.
[4] E. Ingelsson,et al. Circulating proteins as predictors of incident heart failure in the elderly , 2018, European journal of heart failure.
[5] Gianluigi Savarese,et al. A comprehensive population‐based characterization of heart failure with mid‐range ejection fraction , 2017, European journal of heart failure.
[6] E. Ingelsson,et al. Use of Proteomics To Investigate Kidney Function Decline over 5 Years. , 2017, Clinical journal of the American Society of Nephrology : CJASN.
[7] Sanjiv J. Shah,et al. Designing Future Clinical Trials in Heart Failure With Preserved Ejection Fraction: Lessons From TOPCAT , 2017, Current Heart Failure Reports.
[8] A. Low,et al. Thymosin Beta‐4 Is Elevated in Women With Heart Failure With Preserved Ejection Fraction , 2017, Journal of the American Heart Association.
[9] P. Wei,et al. Serum Endothelial Cell–Specific Molecule 1 (Endocan) Levels in Patients With Acute Myocardial Infarction and Its Clinical Significance , 2017, Angiology.
[10] B. van Guelpen,et al. The Metabolic Syndrome, Inflammation, and Colorectal Cancer Risk: An Evaluation of Large Panels of Plasma Protein Markers Using Repeated, Prediagnostic Samples , 2017, Mediators of inflammation.
[11] Sanjiv J. Shah,et al. Mode of Death in Heart Failure With Preserved Ejection Fraction. , 2017, Journal of the American College of Cardiology.
[12] J. Daubert,et al. Inflammatory Biomarkers Predict Heart Failure Severity and Prognosis in Patients With Heart Failure With Preserved Ejection Fraction: A Holistic Proteomic Approach , 2017, Circulation. Cardiovascular genetics.
[13] E. Hagström,et al. Discovery of new biomarkers for atrial fibrillation using a custom-made proteomics chip , 2016, Heart.
[14] J. Blomster,et al. Insulin resistance, endothelial function, angiogenic factors and clinical outcome in non-diabetic patients with chest pain without myocardial perfusion defects , 2016, Cardiovascular Diabetology.
[15] L. Lund,et al. Microvascular endothelial dysfunction in heart failure with preserved ejection fraction , 2016, Heart.
[16] R. McKelvie,et al. Characterization of subgroups of heart failure patients with preserved ejection fraction with possible implications for prognosis and treatment response , 2015, European journal of heart failure.
[17] L. Lund,et al. New echocardiographic predictors of clinical outcome in patients presenting with heart failure and a preserved left ventricular ejection fraction: a subanalysis of the Ka (Karolinska) Ren (Rennes) Study , 2015, European journal of heart failure.
[18] Jacob P. Kelly,et al. Patient selection in heart failure with preserved ejection fraction clinical trials. , 2015, Journal of the American College of Cardiology.
[19] Michael A. Burke,et al. Phenomapping for Novel Classification of Heart Failure With Preserved Ejection Fraction , 2015, Circulation.
[20] Giuseppe Ambrosio,et al. New strategies for heart failure with preserved ejection fraction: the importance of targeted therapies for heart failure phenotypes. , 2014, European heart journal.
[21] J. Daubert,et al. Association between cardiovascular vs. non‐cardiovascular co‐morbidities and outcomes in heart failure with preserved ejection fraction , 2014, European journal of heart failure.
[22] Cynthia Balion,et al. BNP and NT-proBNP as prognostic markers in persons with chronic stable heart failure , 2014, Heart Failure Reviews.
[23] Sanjiv J. Shah,et al. Developing therapies for heart failure with preserved ejection fraction: current state and future directions. , 2014, JACC. Heart failure.
[24] L. Lund,et al. Predicting survival in heart failure: validation of the MAGGIC heart failure risk score in 51 043 patients from the Swedish Heart Failure Registry , 2014, European journal of heart failure.
[25] W. Paulus,et al. A novel paradigm for heart failure with preserved ejection fraction: comorbidities drive myocardial dysfunction and remodeling through coronary microvascular endothelial inflammation. , 2013, Journal of the American College of Cardiology.
[26] Karl Swedberg,et al. Predicting survival in heart failure: a risk score based on 39 372 patients from 30 studies. , 2013, European heart journal.
[27] A. Alwan. Global status report on noncommunicable diseases 2010. , 2011 .
[28] M. Al Banchaabouchi,et al. Antioxidant Amelioration of Dilated Cardiomyopathy Caused by Conditional Deletion of NEMO/IKK&ggr; in Cardiomyocytes , 2010, Circulation research.
[29] A. Nobel,et al. Supervised risk predictor of breast cancer based on intrinsic subtypes. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[30] J. Daubert,et al. Rationale and design of the Karolinska‐Rennes (KaRen) prospective study of dyssynchrony in heart failure with preserved ejection fraction , 2009, European journal of heart failure.
[31] Max Kuhn,et al. Building Predictive Models in R Using the caret Package , 2008 .
[32] V. Roger,et al. Trends in prevalence and outcome of heart failure with preserved ejection fraction. , 2006, The New England journal of medicine.
[33] Richard T. Lee,et al. Identification of Serum Soluble ST2 Receptor as a Novel Heart Failure Biomarker , 2003, Circulation.
[34] Adrian E. Raftery,et al. Model-Based Clustering, Discriminant Analysis, and Density Estimation , 2002 .
[35] R. Tibshirani,et al. Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications , 2001, Proceedings of the National Academy of Sciences of the United States of America.
[36] M. Kendall. Statistical Methods for Research Workers , 1937, Nature.
[37] R. Fisher,et al. Statistical Methods for Research Workers , 1930, Nature.